Genmab's zalutumumab fails Phase III trial in refractory head and neck cancer
This article was originally published in Scrip
Executive Summary
Genmab's experimental EGFR-targeted monoclonal antibody zalutumumab (HuMax-EGFr), one of its most advanced products in development, has failed to meet its primary overall survival endpoint in its first pivotal Phase III trial, in refractory head and neck cancer. Genmab shares fell by 20% on March 8th on the news.